Baseline FIB ‐4 May Be a Risk Factor of Recurrence After SBRT in Patients With HBV ‐Related Small HCC
Cancer Medicine · 2025
DOI: 10.1002/cam4.70535 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Zhan Zeng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Radiosurgery, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Municipal Science and Technology Commission of Major Projects, National Science and Technology Major for Infectious Diseases, National Science and Technology Major Special Project for New Drug Development.
Abstract (Originalsprache)
Aims
Exploring fibrosis index‐4 (FIB‐4)'s predictive value for HBV‐related hepatocellular carcinoma (HCC) in assessing recurrence following stereotactic body radiation therapy (SBRT) in patients with HBV‐related HCC.
Methods
HBV‐related HCC patients who underwent SBRT were retrospectively enrolled from March 2012 to March 2020. Patients were divided into recurrence and non‐recurrence groups based on the HCC recurrence situation. Baseline data were collected from all patients before treatment and at 3 and 6 months after treatment, and FIB‐4 was calculated at the corresponding time points. Risk factors were selected using Cox regression. The FIB‐4 was stratified for survival analysis.
Results
One hundred and fifty‐two patients were included. With a mean age of 53.5 years old, 94.1% of them had liver cirrhosis. The median recurrence‐free survival (RFS) time for recurrent patients was 17.5 months. The tumor response rate of SBRT was 94.8%. HCC recurrence rates at 12, 24, 36, 48, and 60 months were 19.7% (30/152), 38.2% (58/152), 48.0% (73/152), 52.0% (79/152), and 53.3% (81/152), respectively. Cox regression showed that baseline FIB‐4 (95% CI: 1.030 ~ 1.144, p = 0.002) and 3 tumor nodules (95% CI: 3.727 ~ 260.663, p = 0.002) are risk factors for HCC recurrence. Patients with a baseline FIB‐4 > 6.55 were at a higher risk of HCC recurrence than those with a baseline FIB‐4 < 6.55 ( p < 0.001).
Conclusion
Baseline FIB‐4 is a risk factor for recurrence after SBRT in patients with HBV‐related HCC, and the predictive threshold for FIB‐4 is higher in patients with cirrhosis. For patients who received radiotherapy, postoperative FIB‐4 levels are elevated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infectious Diseases, Peking University First Hospital, Beijing, China.
- Department of Gastroenterology, Peking University First Hospital, Beijing, China.
- Radiation Oncology Department, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
ORCID-Profile: Zhan Zeng
Förderung
- Beijing Municipal Science and Technology Commission of Major Projects
- National Science and Technology Major for Infectious Diseases
- National Science and Technology Major Special Project for New Drug Development
Zitieren
APA
Zeng, Z., Han, Y., Li, W., Chen, H., Lin, N., Yu, Y., & Xu, X. (2025). Baseline FIB ‐4 May Be a Risk Factor of Recurrence After SBRT in Patients With HBV ‐Related Small HCC. Cancer Medicine. https://doi.org/10.1002/cam4.70535
Vancouver
Zeng Z, Han Y, Li W, Chen H, Lin N, Yu Y, et al. Baseline FIB ‐4 May Be a Risk Factor of Recurrence After SBRT in Patients With HBV ‐Related Small HCC. Cancer Medicine. 2025. doi:10.1002/cam4.70535
BibTeX
@article{Zeng2025,
author = {Zeng, Zhan and Han, Yifan and Li, Wengang and Chen, Hongyu and Lin, Ning and Yu, Yanyan and Xu, Xiaoyuan},
title = {Baseline FIB ‐4 May Be a Risk Factor of Recurrence After SBRT in Patients With HBV ‐Related Small HCC},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70535}
}
EUVIMED